Protagonist Therapeutics, Inc Quarterly Debt-to-equity in % from Q1 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Protagonist Therapeutics, Inc quarterly Debt-to-equity history and growth rate from Q1 2018 to Q3 2024.
  • Protagonist Therapeutics, Inc Debt-to-equity for the quarter ending September 30, 2024 was 11.9 %, a 11.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 11.9 +1.22 +11.4% Sep 30, 2024
Q2 2024 11 -1.49 -11.9% Jun 30, 2024
Q1 2024 9.67 -4.87 -33.5% Mar 31, 2024
Q4 2023 8.64 -6.91 -44.5% Dec 31, 2023
Q3 2023 10.7 -5.02 -31.9% Sep 30, 2023
Q2 2023 12.5 -2.55 -17% Jun 30, 2023
Q1 2023 14.5 +0.22 +1.54% Mar 31, 2023
Q4 2022 15.5 +1.37 +9.66% Dec 31, 2022
Q3 2022 15.7 +1.56 +11% Sep 30, 2022
Q2 2022 15 -1.68 -10.1% Jun 30, 2022
Q1 2022 14.3 -7.24 -33.6% Mar 31, 2022
Q4 2021 14.2 -18.6 -56.7% Dec 31, 2021
Q3 2021 14.2 -38.4 -73% Sep 30, 2021
Q2 2021 16.7 -48.4 -74.3% Jun 30, 2021
Q1 2021 21.6 -62.3 -74.3% Mar 31, 2021
Q4 2020 32.7 -30.9 -48.6% Dec 31, 2020
Q3 2020 52.6 +6.45 +14% Sep 30, 2020
Q2 2020 65.1 +30.2 +86.6% Jun 30, 2020
Q1 2020 83.9 +58.4 +230% Mar 31, 2020
Q4 2019 63.7 +38.3 +151% Dec 31, 2019
Q3 2019 46.2 +17.8 +62.8% Sep 30, 2019
Q2 2019 34.9 -5.07 -12.7% Jun 30, 2019
Q1 2019 25.4 -14.1 -35.6% Mar 31, 2019
Q4 2018 25.4 Dec 31, 2018
Q3 2018 28.4 Sep 30, 2018
Q2 2018 40 Jun 30, 2018
Q1 2018 39.5 Mar 31, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.